Population pharmacokinetic analyses for belzutifan to inform dosing considerations and labeling

Belzutifan (Welireg, Merck & Co., Inc., Rahway, NJ, USA) is an oral, potent inhibitor of hypoxia‐inducible factor 2α, approved for the treatment of certain patients with von Hippel–Lindau (VHL) disease‐associated renal cell carcinoma (RCC), central nervous system hemangioblastomas, and pancreati...

Descripción completa

Detalles Bibliográficos
Autores principales: Marathe, Dhananjay D., Jauslin, Petra M., Kleijn, Huub Jan, de Miranda Silva, Carolina, Chain, Anne, Bateman, Thomas, Shaw, Peter M., Abraham, Anson K., Kauh, Eunkyung A., Liu, Yanfang, Perini, Rodolfo F., de Alwis, Dinesh P., Jain, Lokesh
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
Research
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583240/
https://www.ncbi.nlm.nih.gov/pubmed/37596839
http://dx.doi.org/10.1002/psp4.13028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10583240/
https://www.ncbi.nlm.nih.gov/pubmed/37596839
http://dx.doi.org/10.1002/psp4.13028

Ejemplares similares